Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...

Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...

Here are some key strategies you can use to help your teams develop the skills needed to excel as executive-level presenters.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

What if you could generate an entire professional deck in minutes? Enter AI-powered presentation makers. These tools are ...

(Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, ...

Several dozen people attended a recent presentation on the "Impact of the Data Center Boom on Virginia Communities" sponsored by a newly formed group called Winchester-area Interfaith ...

Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.

Keeping up with technology can be difficult for many people as artificial intelligence is a relatively new tool that has ...